Mozart Therapeutics
Russ Hawkinson currently serves as the Chief Financial Officer at Mozart Therapeutics, Inc., a position held since September 2023. Prior to this role, Hawkinson was the Senior Vice President of Finance at Silverback Therapeutics from April 2020 to November 2022. Previously, experience includes serving as CFO at OncoResponse and Theraclone Sciences, and held the position of VP Finance at both Cell Therapeutics, Inc. and Corixa. Early career experience includes a Senior Manager role in Audit at Ernst & Young from October 1986 to November 1999. Hawkinson's educational background includes studies at the University of Washington from 1984 to 1986.
Mozart Therapeutics
Mozart Therapeutics is a biotech startup focusing on the development of disease-modifying therapies for autoimmune and inflammatory diseases. The company is using a novel regulatory CD8 T cell network to create disease-modifying CD8 Treg modulators for a variety of autoimmune diseases. Mozart is developing a pipeline of first-in-class 'CD8Treg modulators with the goal of restoring long-term immune balance and preventing the progressive damage caused by an autoreactive and pathogenic immune response.